Neumora Therapeutics, Inc. (Nasdaq: NMRA) announced its financial results for the third quarter ended September 30, 2026, alongside an update on its clinical pipeline. The company reported a net loss of $34.4 million for the quarter, a decrease from the $56.8 million loss reported in the same period in 2025. Research and development expenses for the third quarter of 2026 were $22.6 million, down from $40.5 million in 2025, while general and administrative expenses were $10.8 million, compared to $12.2 million in the prior year.
As of September 30, 2026, Neumora held cash and cash equivalents of $85.7 million. The company stated it is not providing updated financial runway guidance, noting that to continue operations and complete the development of its product candidates, substantial additional funding will be required.
In terms of business updates, Neumora submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for NMRA-215, a brain-penetrant oral NLRP3 inhibitor intended for obesity and cardiometabolic disease. Preclinical data presented at ObesityWeek 2026 indicated NMRA-215 achieved class-leading weight loss of up to 19% as a monotherapy and up to 26% when combined with semaglutide in diet-induced obesity mouse studies.
Regarding NMRA-511, a vasopressin 1a receptor antagonist, the company reported results from a Multiple Ascending Dose (MAD) expansion cohort. The 30 mg twice-daily dose demonstrated a favorable safety and tolerability profile with no serious adverse events and dose-proportional increases in exposure compared to the 20 mg dose used in a Phase 1b study. The company believes the 30 mg dose may support the efficacy profile seen in the Phase 1b study and has indicated the program is Phase 2 enabled. Additionally, the Phase 1 MAD study for NMRA-898, an M4 Positive Allosteric Modulator, is ongoing in healthy volunteers and patients with stable schizophrenia.